Bassler Bonnie L — SEC Form 4 filings
SEC reporting owner CIK 1683607. 27 Form 4 filings on record with FilingPulse; latest filed 2026-06-30.
Transaction summary — filings shown
Covers all 27 filings on record, filed 2024-01-31 to 2026-06-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 8 legs across 8 filings — 7,036 shares, $6,765,802 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 44.
- Largest priced transaction: sale of 1,500 shares @ $800.00 ($1,200,000) in REGENERON PHARMACEUTICALS, INC., filed 2026-01-08.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC. (REGN) | Director | 10 | — | 8 legs · 7,036 sh · $6,765,802 | 20 |
| Royalty Pharma plc (RPRX) | Director | 13 | — | — | 13 |
| Cidara Therapeutics, Inc. (CDTX) | Director | 4 | — | — | 11 |
Form 4 filings — Bassler Bonnie L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 689 @ $54.40 | EDGAR |
| 2026-06-08 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 4,545 @ $0 | EDGAR |
| 2026-03-31 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 815 @ $45.98 | EDGAR |
| 2026-01-08 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 1,500 @ $374.12 · Sale (S): 1,500 @ $800 · Option exercise (M): 1,500 (derivative) @ $0 | EDGAR |
| 2026-01-07 | 4 | Cidara Therapeutics, Inc. (CDTX) | Disposition to issuer (D): 15 @ $221.50 · Disposition to issuer (D): 1,750 (derivative) · Disposition to issuer (D): 875 (derivative) · Disposition to issuer (D): 1,400 (derivative) · Disposition to issuer (D): 2,125 (derivative) · Disposition to issuer (D): 2,125 (derivative) · +2 more | EDGAR |
| 2026-01-06 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0 | EDGAR |
| 2026-01-02 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 967 @ $38.74 | EDGAR |
| 2025-11-24 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 760 @ $371.40 · Sale (S): 760 @ $750 · Option exercise (M): 760 (derivative) @ $0 | EDGAR |
| 2025-09-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,047 @ $35.79 | EDGAR |
| 2025-06-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,064 @ $35.24 | EDGAR |
| 2025-06-18 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 11,100 (derivative) @ $0 | EDGAR |
| 2025-05-14 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 7,614 @ $0 | EDGAR |
| 2025-04-01 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,141 @ $32.87 | EDGAR |
| 2025-01-06 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Grant/award (A): 166 @ $0 · Grant/award (A): 1,958 (derivative) @ $0 | EDGAR |
| 2025-01-02 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,503 @ $24.94 | EDGAR |
| 2024-12-19 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-09-30 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,342 @ $27.92 | EDGAR |
| 2024-08-19 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,170 · Option exercise (M): 756 (derivative) @ $0 | EDGAR |
| 2024-08-05 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,115 · Option exercise (M): 756 (derivative) @ $0 | EDGAR |
| 2024-07-19 | 4 | Cidara Therapeutics, Inc. (CDTX) | Grant/award (A): 2,125 (derivative) @ $0 | EDGAR |
| 2024-06-28 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,399 @ $26.80 | EDGAR |
| 2024-06-25 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,062 · Option exercise (M): 756 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 9,293 @ $0 | EDGAR |
| 2024-06-07 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 827 @ $380.95 · Sale (S): 827 @ $1,011 · Option exercise (M): 827 (derivative) @ $0 | EDGAR |
| 2024-04-02 | 4 | Royalty Pharma plc (RPRX) | Grant/award (A): 1,240 @ $30.23 | EDGAR |
| 2024-02-26 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 854 @ $391.92 · Sale (S): 854 @ $979.25 · Option exercise (M): 854 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | REGENERON PHARMACEUTICALS, INC. (REGN) | Option exercise (M): 827 @ $380.95 · Sale (S): 827 @ $959 · Option exercise (M): 827 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1683607 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →